Schizophrenia
- Health
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
Ingelheim, Germany: Results presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has…
Read More » - Business
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Ingelheim, Germany: This collaboration combines Click Therapeutics’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in…
Read More »